Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. firmnews.title_view.
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Merck has high Keytruda hopes outside U.S., but Q1 details sparse | Fierce Pharma
Merck & Co's Keytruda rejected by UK NICE in advanced kidney cancer | S&P Global Market Intelligence
Merck Hikes Forecast as Keytruda Tops $3 Billion for Quarter - Bloomberg
FDA approves Keytruda for high-risk, early-stage triple-negative breast cancer
Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut - WSJ
US FDA panel backs Merck & Co.'s Keytruda to treat type of bladder cancer | S&P Global Market Intelligence
FDA Approves Mercks KEYTRUDA® for Patients with Recurrent or Metastatic Head and Neck Cancer | World Pharma Today
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients - AIM at Melanoma Foundation
Merck's Keytruda gets boost in kidney and head and neck cancer | pharmaphorum
Promega collaborate with Merck to develop MSI CDx for use with Keytruda
Keytruda Approved by FDA for Further Potential Treatments of Mesothelioma | Mesothelioma Help Cancer Organization
US FDA approves Merck & Co.'s Keytruda in 2 new head, neck cancer uses | S&P Global Market Intelligence
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer | PharmiWeb.Jobs United States
Moderna on X: "We announced today that mRNA-4157/V940, an investigational personalized #mRNA #cancer vaccine, in combination with KEYTRUDA, @Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S. FDA for
Asco 2018 – Merck's dominance leaves rivals scrabbling for subsets | Evaluate
ASCO: Can Keytruda expand further in first-line cervical cancer?
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced The Risk Of Distant Metastasis Or Death By 40% Compared Versus Placebo As Adjuvant Treatment In Resected, High-Risk Stage III Melanoma 2023 - EORTC
FDA Adcom Gives Merck's Keytruda a Surprise Thumbs Down | BioSpace
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
FDA Approves Combining Merck's Keytruda With Chemotherapy in Lung Cancer Patients - WSJ
Merck's PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma - Cancer Research Institute
